The Hatch-Waxman Act

The Hatch-Waxman Act — formally the Drug Price Competition and Patent Term Restoration Act of 1984 — is the federal law that created the legal framework for both generic drug approval and pharmaceutical patent protection in the United States. It was passed as a compromise between two competing interests: the pharmaceutical industry wanted stronger patent protection for innovator drugs; the generic industry wanted a streamlined approval process that didn't require repeating expensive clinical trials for drugs already shown to be safe and effective. The act simultaneously: (1) Created the Abbreviated New Drug Application (ANDA) process — allowing generic drug companies to get FDA approval by demonstrating bioequivalence to an approved reference drug, without conducting independent clinical trials; (2) Created the Orange Book — a public FDA database listing all patents covering approved drugs; (3) Created the Paragraph IV certification mechanism — allowing generic companies to challenge orange-book-listed patents by certifying they are invalid or not infringed; (4) Created the 30-month automatic stay — giving brand-name companies time to litigate challenged patents before generics enter the market; (5) Created 180-day first-filer exclusivity — rewarding the first generic applicant with a period of market exclusivity; (6) Created patent term extension (PTE) under 35 U.S.C. § 156 — restoring patent time lost during FDA regulatory review (up to 5 additional years). The Act was named after its primary sponsors, Senator Orrin Hatch (R-Utah) and Representative Henry Waxman (D-California). The 1984 Act has been significantly amended, most notably by the Medicare Modernization Act of 2003 which reformed the 30-month stay rules to prevent brand-name companies from stacking multiple stays by listing new patents.

The Orange Book (officially FDA's 'Approved Drug Products with Therapeutic Equivalence Evaluations') is a publicly available FDA database listing: (1) all FDA-approved drug products; (2) patents covering those products that meet the Orange Book listing criteria; and (3) therapeutic equivalence ratings. Why patents are listed: the NDA holder is required to submit to the FDA information about each patent that claims the drug or the method of using the drug for a condition claimed in the NDA. Only certain types of patents qualify for Orange Book listing: patents claiming the active ingredient, formulation/composition, and approved method of use. Drug substance synthesis patents and packaging patents are NOT listable. IMPROPER LISTING RISK: listing a patent that should not be listed, or listing with an overbroad 'use code' description, exposes the NDA holder to antitrust liability (Walker Process fraud on FDA) and Hatch-Waxman counterclaim exposure (Caraco v. Novo Nordisk). Orange Book listing is critical because: (a) each listed patent requires a separate certification from the ANDA applicant; (b) a Paragraph IV certification against a listed patent can trigger a 30-month stay; (c) patents not listed in the Orange Book cannot support a Paragraph IV lawsuit and cannot trigger a 30-month stay. Orange Book patent types accepted: (a) Drug substance (active ingredient) patents: claim the API in any form (free acid, base, salt, polymorph); (b) Drug product (formulation) patents: claim specific drug product formulations, dosage forms, or delivery systems; (c) Method of use patents: claim the approved therapeutic indication for using the drug. The Orange Book is updated daily and is freely available on the FDA's website.

The 30-month stay is an automatic FDA approval delay that triggers when: (1) a generic company files an ANDA with a Paragraph IV certification (challenging an Orange Book-listed patent as invalid, unenforceable, or not infringed); (2) the generic company sends the required notice to the NDA holder and patent owner; (3) the NDA holder or patent owner files a patent infringement lawsuit within 45 days of receiving the notice; and all three conditions are met. How the stay works: Once the 30-month stay is triggered, the FDA cannot approve the ANDA for 30 months from the date the NDA holder received the Paragraph IV notice. The 30 months run from notice receipt, not from the date the lawsuit was filed. The stay terminates EARLIER than 30 months if: (a) a court rules the patent is invalid, unenforceable, or not infringed — the FDA can immediately approve the ANDA; (b) the court enters a consent judgment or the parties settle and stipulate to certain terms; (c) the brand-name company voluntarily withdraws the lawsuit. The stay can be EXTENDED beyond 30 months by the court if the ANDA applicant failed to reasonably cooperate in discovery. What happens if no lawsuit is filed within 45 days: the 30-month stay does not trigger. The FDA may immediately approve the ANDA if all other requirements are satisfied. Post-2003 reform: after the Medicare Modernization Act of 2003, the 30-month stay applies only ONCE per ANDA — the brand-name company cannot list new patents and trigger additional 30-month stays after the first Para IV certification. This eliminated the brand-name tactic of listing patents serially to stack multiple stays. Litigation under the stay: during the 30-month stay period, the district court adjudicates the patent validity/infringement case. Approximately 75–80% of Hatch-Waxman paragraph IV cases settle, often with the generic agreeing to delay entry until a specified date in exchange for dropping invalidity claims (creating the 'pay-for-delay' controversy addressed in FTC v. Actavis, S.Ct. 2013).

The 180-day first-filer exclusivity is one of the most commercially valuable rights in pharmaceutical law. The FIRST ANDA applicant to file a Paragraph IV certification for a given drug (the 'first filer') receives 180 days of generic market exclusivity — for 180 days after the first filer begins commercial marketing, no other ANDA applicant can enter the market. This means the first filer is the sole generic competitor for six months. During this period, the first filer can price its drug near the brand-name price rather than the commodity price that emerges once 10–20 generics compete. The commercial value: for a blockbuster drug with $1B+ in annual US sales, the first six months of generic exclusivity can be worth hundreds of millions of dollars — often exceeding the cost of the Paragraph IV litigation. Forfeiture provisions under 21 U.S.C. § 505(j)(5)(D): the first filer FORFEITS the 180-day exclusivity if any of the following occurs: (1) Failure to market within 75 days of: a court judgment that the relevant Orange Book patents are invalid or not infringed; OR the 30-month stay expiring (if no court judgment); OR the ANDA being approved by FDA — whichever is earliest; (2) Withdrawal of the Paragraph IV ANDA; (3) Failure to obtain tentative approval within 30 months of ANDA filing (due to first filer's own deficiencies, not FDA delay); (4) First filer enters into an agreement with the brand-name company that the FTC determines is a violation of antitrust law; (5) Delisting of the patent from the Orange Book; (6) Patent being found invalid or unenforceable in a Federal Circuit or Supreme Court decision; (7) Shared exclusivity: if multiple generic companies filed their ANDAs on the same day with a Para IV certification, they may all share the 180-day exclusivity (the 'first filer' can be a group). The 180-day exclusivity is a critical commercial right that drives the significant investment generic companies make in Paragraph IV patent challenges — often spending tens of millions of dollars on litigation to win the first-filer prize for a major drug.

Patent term extension (PTE) under 35 U.S.C. § 156 (the Hatch-Waxman patent term restoration provision) compensates patent holders for time lost during FDA regulatory review. The formula: PTE = ½ × (IND clinical period) + full FDA review period. IND clinical period: the time between submission of the IND (Investigational New Drug application, which begins clinical testing in humans) and submission of the NDA/BLA (New Drug Application/Biologics License Application) to the FDA. Only ½ of this period counts toward PTE because the applicant has 'commercial marketing rights' during clinical testing (theoretically). FDA review period: the full time from NDA/BLA submission to FDA approval. This entire period counts because the patent holder is entirely blocked from commercializing the drug during this time. Maximum limits: (a) The PTE may not exceed 5 years; (b) The remaining term of the patent after FDA approval cannot exceed 14 years (any PTE that would result in more than 14 remaining years is capped). PTE application: must be filed within 60 days of FDA approval — this deadline is strict with no extensions. Late filing = no PTE. Application filed with USPTO, which calculates the PTE based on FDA records. Offset by PTA: the PTE is reduced by any patent term adjustment (PTA) days earned during prosecution — to prevent double-counting of delays. Eligible patents: only ONE patent per product (NDA/BLA) may be extended; that patent must claim the approved drug product, a method of using it, or the method of manufacturing it; the patent must be in force at the time of approval; and the patent must not have been previously extended under § 156. Pediatric exclusivity (separate): if the brand-name company conducts FDA-required pediatric studies, it receives 6 months of 'pediatric exclusivity' that is added to ALL Orange Book-listed patents simultaneously — not just one patent. This is separate from PTE and often worth more because it extends multiple patents rather than just the one selected for PTE.